At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study in Comparing the Efficacy and Safety of Peginterferon Alfa-2a and Interferon Alfa-2a in Treating Patients With End Stage Renal Disease and Chronic Hepatitis C
In Brief
A Phase 4 clinical trial evaluating Peginterferon alfa-2a and Interferon alfa-2a for Chronic Hepatitis C and End Stage Renal Disease. Completed, enrolled 50 participants across 1 site.
Detailed Summary
The treatment response with conventional interferon alpha alone in patients with end stage renal disease and chronic hepatitis C is about 33-39%. However, the drop-out rate is 17-29.6%. Pegylated interferon alpha, a newly developed form of interferon with superior pharmacokinetic profiles, has not been used to treatment these patients. We expect the better treatment response treated with peginterferon alpha than conventional interferon. In addition, we also observe the safety of the two drugs during the study. The goal of the study is to compare the efficacy and safety of the two different treatment regimens in patients with chronic hepatitis C and end stage renal disease.
Study Details
Timeline
Interventions
Peginterferon alfa-2a 135 ug/week for 24 weeks
Interferon alfa-2a 3 MU tiw for 24 weeks